Consensus clustering methodology to improve molecular stratification of non-small cell lung cancer.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
12 05 2023
Historique:
received: 14 07 2022
accepted: 21 04 2023
medline: 15 5 2023
pubmed: 13 5 2023
entrez: 12 5 2023
Statut: epublish

Résumé

Recent advances in machine learning research, combined with the reduced sequencing costs enabled by modern next-generation sequencing, paved the way to the implementation of precision medicine through routine multi-omics molecular profiling of tumours. Thus, there is an emerging need of reliable models exploiting such data to retrieve clinically useful information. Here, we introduce an original consensus clustering approach, overcoming the intrinsic instability of common clustering methods based on molecular data. This approach is applied to the case of non-small cell lung cancer (NSCLC), integrating data of an ongoing clinical study (PROMOLE) with those made available by The Cancer Genome Atlas, to define a molecular-based stratification of the patients beyond, but still preserving, histological subtyping. The resulting subgroups are biologically characterized by well-defined mutational and gene-expression profiles and are significantly related to disease-free survival (DFS). Interestingly, it was observed that (1) cluster B, characterized by a short DFS, is enriched in KEAP1 and SKP2 mutations, that makes it an ideal candidate for further studies with inhibitors, and (2) over- and under-representation of inflammation and immune systems pathways in squamous-cell carcinomas subgroups could be potentially exploited to stratify patients treated with immunotherapy.

Identifiants

pubmed: 37173325
doi: 10.1038/s41598-023-33954-x
pii: 10.1038/s41598-023-33954-x
pmc: PMC10182023
doi:

Substances chimiques

Kelch-Like ECH-Associated Protein 1 0
NF-E2-Related Factor 2 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

7759

Informations de copyright

© 2023. The Author(s).

Références

Nat Genet. 2015 Feb;47(2):106-14
pubmed: 25501392
Clin Colorectal Cancer. 2019 Jun;18(2):91-101.e3
pubmed: 30981604
Nat Genet. 2000 May;25(1):25-9
pubmed: 10802651
Oncol Rep. 2020 Dec;44(6):2386-2396
pubmed: 33125148
Bioinformatics. 2020 Jul 1;36(Suppl_1):i389-i398
pubmed: 32657401
Mol Cancer Ther. 2021 Sep;20(9):1692-1701
pubmed: 34158350
BMC Bioinformatics. 2021 Jul 6;22(1):361
pubmed: 34229612
Cell Syst. 2019 Jul 24;9(1):24-34.e10
pubmed: 31344359
Bioinformatics. 2020 Feb 15;36(4):1159-1166
pubmed: 31501851
Surg Oncol Clin N Am. 2016 Jul;25(3):447-68
pubmed: 27261908
Oncotarget. 2017 Jan 3;8(1):133-144
pubmed: 27863400
Genes (Basel). 2018 Jun 21;9(7):
pubmed: 29933539
Nature. 2013 Jul 11;499(7457):214-218
pubmed: 23770567
Nat Methods. 2013 Nov;10(11):1108-15
pubmed: 24037242
Pharmacol Res. 2022 Jul;181:106259
pubmed: 35577307
Chin Clin Oncol. 2015 Sep;4(3):33
pubmed: 26408300
J Natl Cancer Inst. 2020 Oct 1;112(10):1021-1029
pubmed: 31922567
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Cell. 2017 Feb 9;168(4):613-628
pubmed: 28187284
Cells. 2021 Feb 05;10(2):
pubmed: 33562741
Psychometrika. 1967 Sep;32(3):241-54
pubmed: 5234703
Sci Rep. 2018 Oct 1;8(1):14576
pubmed: 30275546
J Thorac Oncol. 2016 Dec;11(12):2150-2160
pubmed: 27498386
Biostatistics. 2018 Jan 1;19(1):71-86
pubmed: 28541380
Bioinformatics. 2011 Jun 15;27(12):1739-40
pubmed: 21546393
J Surg Oncol. 2010 May 1;101(6):500-6
pubmed: 20213688
Cell. 2018 Sep 6;174(6):1347-1360
pubmed: 30193109
Oncogene. 2010 Jul 29;29(30):4307-16
pubmed: 20514026
Tumour Biol. 2016 Mar;37(3):3925-31
pubmed: 26482610
Nat Methods. 2014 Mar;11(3):333-7
pubmed: 24464287
PLoS One. 2021 Nov 29;16(11):e0260500
pubmed: 34843570
Genome Biol. 2020 May 11;21(1):111
pubmed: 32393329
Sci Rep. 2019 Mar 1;9(1):3235
pubmed: 30824826
BMJ. 2004 May 1;328(7447):1073
pubmed: 15117797
BMC Bioinformatics. 2011 Aug 04;12:323
pubmed: 21816040
Interdiscip Sci. 2018 Dec;10(4):836-847
pubmed: 30039492
Bioinformatics. 2016 Oct 1;32(19):3047-8
pubmed: 27312411
Bioinformatics. 2009 Nov 15;25(22):2906-12
pubmed: 19759197
Curr Mol Med. 2015;15(5):418-32
pubmed: 25941815
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Ann Appl Stat. 2013 Mar 1;7(1):523-542
pubmed: 23745156
BMC Bioinformatics. 2003 Dec 02;4:60
pubmed: 14651757
Cancers (Basel). 2019 Jul 26;11(8):
pubmed: 31357501
CA Cancer J Clin. 2017 Mar;67(2):138-155
pubmed: 28140453
Proc Natl Acad Sci U S A. 2013 Mar 12;110(11):4245-50
pubmed: 23431203
J Clin Invest. 2012 Sep;122(9):3197-210
pubmed: 22886302
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Sci Rep. 2017 Dec 5;7(1):16954
pubmed: 29209073
Contemp Oncol (Pozn). 2015;19(1A):A68-77
pubmed: 25691825
Bioinformatics. 2016 Jan 1;32(1):1-8
pubmed: 26377073
J Clin Oncol. 2022 Feb 20;40(6):611-625
pubmed: 34985916
Onco Targets Ther. 2017 Jan 18;10:439-446
pubmed: 28176922
Sci Rep. 2020 Dec 3;10(1):21128
pubmed: 33273537
Front Genet. 2019 Mar 26;10:214
pubmed: 30972100
J Clin Oncol. 2021 Nov 10;39(32):3527-3530
pubmed: 34559549
Front Genet. 2019 Mar 08;10:166
pubmed: 30906311
Cancer Discov. 2022 Jan;12(1):31-46
pubmed: 35022204
Oncologist. 2020 Sep;25(9):733-737
pubmed: 32396674
N Engl J Med. 2007 Jan 4;356(1):11-20
pubmed: 17202451
Clin Lung Cancer. 2022 Sep;23(6):e347-e352
pubmed: 35697558
N Engl J Med. 2017 Jun 22;376(25):2415-2426
pubmed: 28636851
Cancer Res. 2002 Jun 1;62(11):3005-8
pubmed: 12036904
BMC Bioinformatics. 2002 Nov 24;3:36
pubmed: 12445336
J Clin Oncol. 2005 Dec 1;23(34):8664-70
pubmed: 16260700
J Thorac Oncol. 2017 Jun;12(6):943-953
pubmed: 28341226
Mol Syst Biol. 2018 Jun 20;14(6):e8124
pubmed: 29925568

Auteurs

L Manganaro (L)

aizoOn Technology Consulting S.R.L, Torino, Italy.

S Bianco (S)

aizoOn Technology Consulting S.R.L, Torino, Italy.

P Bironzo (P)

Medical Oncology Division at San Luigi Hospital, Department of Oncology, University of Torino, Orbassano (TO), Italy.

F Cipollini (F)

aizoOn Technology Consulting S.R.L, Torino, Italy.

D Colombi (D)

aizoOn Technology Consulting S.R.L, Torino, Italy.

D Corà (D)

Department of Translational Medicine, Piemonte Orientale University, Novara, Italy.
Center for Translational Research on Autoimmune and Allergic Diseases-CAAD, Novara, Italy.

G Corti (G)

Department of Oncology, University of Torino, 10060, Candiolo, Italy.
Candiolo Cancer Institute-IRCCS-FPO, 10060, Candiolo, Italy.

G Doronzo (G)

Department of Oncology, University of Torino, 10060, Candiolo, Italy.
Candiolo Cancer Institute-IRCCS-FPO, 10060, Candiolo, Italy.

L Errico (L)

Division of Thoracic Surgery at AOU San Luigi, Department of Oncology, University of Torino, Orbassano (TO), Italy.

P Falco (P)

aizoOn Technology Consulting S.R.L, Torino, Italy.

L Gandolfi (L)

Department of Oncology, University of Torino, 10060, Candiolo, Italy.
Candiolo Cancer Institute-IRCCS-FPO, 10060, Candiolo, Italy.

F Guerrera (F)

Division of Thoracic Surgery at AOU Città della Salute e della Scienza, Department of Surgical Sciences, University of Torino, Torino, Italy.

V Monica (V)

Department of Oncology, University of Torino, 10060, Candiolo, Italy.
Candiolo Cancer Institute-IRCCS-FPO, 10060, Candiolo, Italy.

S Novello (S)

Medical Oncology Division at San Luigi Hospital, Department of Oncology, University of Torino, Orbassano (TO), Italy.

M Papotti (M)

Pathology Division at AOU Città della Salute e della Scienza, Department of Oncology, University of Torino, Torino, Italy.

S Parab (S)

Department of Oncology, University of Torino, 10060, Candiolo, Italy.
Candiolo Cancer Institute-IRCCS-FPO, 10060, Candiolo, Italy.

A Pittaro (A)

Pathology Division at AOU Città della Salute e della Scienza, Department of Oncology, University of Torino, Torino, Italy.

L Primo (L)

Department of Oncology, University of Torino, 10060, Candiolo, Italy.
Candiolo Cancer Institute-IRCCS-FPO, 10060, Candiolo, Italy.

L Righi (L)

Pathology Division at AOU San Luigi, Department of Oncology, University of Torino, Orbassano (TO), Italy.

G Sabbatini (G)

aizoOn Technology Consulting S.R.L, Torino, Italy.

A Sandri (A)

Division of Thoracic Surgery at AOU San Luigi, Department of Oncology, University of Torino, Orbassano (TO), Italy.

S Vattakunnel (S)

aizoOn Technology Consulting S.R.L, Torino, Italy.

F Bussolino (F)

Department of Oncology, University of Torino, 10060, Candiolo, Italy.
Candiolo Cancer Institute-IRCCS-FPO, 10060, Candiolo, Italy.

G V Scagliotti (GV)

Medical Oncology Division at San Luigi Hospital, Department of Oncology, University of Torino, Orbassano (TO), Italy. giorgio.scagliotti@unito.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH